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 AS-48 is a 70-residue circular
bacteriocin produced by Enterococcus
strains.
 Toxicity of AS-48 in in vitro and in vivo
models has been evaluated.
 The haemolytic activity and lacks of
pro-inflammatory effects of AS-48 are
minimal.
 AS-48 has scarce ability to cause loss
of cell viability at therapeutic
concentrations.
 AS-48 is a promising therapeutic
agent against a vast array of microbial
infections.g r a p h i c a l a b s t r a c t
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Mouse modela b s t r a c t
The in vitro antimicrobial potency of the bacteriocin AS-48 is well documented, but its clinical application
requires investigation, as its toxicity could be different in in vitro (haemolytic and antibacterial activity in
blood and cytotoxicity towards normal human cell lines) and in vivo (e.g. mice and zebrafish embryos)
models. Overall, the results obtained are promising. They reveal the negligible propensity of AS-48 to
cause cell death or impede cell growth at therapeutic concentrations (up to 27 lM) and support the suit-
ability of this peptide as a potential therapeutic agent against several microbial infections, due to its
selectivity and potency at low concentrations (in the range of 0.3–8.9 lM). In addition, AS-48 exhibits
low haemolytic activity in whole blood and does not induce nitrite accumulation in non-stimulated
RAW macrophages, indicating a lack of pro-inflammatory effects. The unexpected heightened sensitivity
of zebrafish embryos to AS-48 could be due to the low differentiation state of these cells. The low cyto-
toxicity of AS-48, the absence of lymphocyte proliferation in vivo after skin sensitization in mice, and the
lack of toxicity in a murine model support the consideration of the broad spectrum antimicrobial peptide
130 R. Cebrián et al. / Journal of Advanced Research 20 (2019) 129–139AS-48 as a promising therapeutic agent for the control of a vast array of microbial infections, in particular,
those involved in skin and soft tissue diseases.
 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Among the diverse array of bacterial metabolites, the superfam-
ily of antimicrobial ribosomal synthesised peptides (bacteriocins)
is biotechnologically relevant for use as natural preservatives to
extend the shelf-life of foods. They display remarkable broad-
spectrum activity against Gram-positive and Gram-negative bacte-
ria, including many antibiotic-resistant strains, often with EC50 val-
ues in the nano- to micromolar range. Currently, interest in
peptides is increasing in pharmaceutical research and develop-
ment. Approximately 140 therapeutic peptides are currently being
evaluated in clinical trials [1]. Additionally, in contrast to many
conventional antibiotics, most of them rapidly kill bacteria instead
of just inhibiting bacterial growth. In general, this effect arises
from their primary structure and properties such as positive net
charge, amphipathicity, conformational flexibility, size, and
hydrophobicity [2]. Although more than 335 bacteriocins have
been described according to the Antimicrobial Peptide Database
(http://aps.unmc.edu/AP/main.php) [3], toxicity data has only been
determined for a few. However, available research and their long
track record of intentional use in food strongly suggest that these
peptides can be safely used. Bacteriocins from lactic acid bacteria
(LAB) exhibit low toxicity against most eukaryotic cells, which
encourages their re-evaluation for clinical/veterinary use as
antimicrobial drugs [4,5]. Their therapeutic potential in local and
systemic bacterial infections is currently under investigation,
underlining their importance as a viable alternative or addition
to currently used antibiotics, considering the increasing spread of
antibiotic resistance. Many bacteriocins fulfil most criteria, includ-
ing low MIC values, low immunogenicity and toxicity, and low
potential to induce resistance, which encourage studies aimed at
marketing them as clinically relevant compounds [6–9]. Interest-
ingly, some recent reports describe very potent bacteriocins pro-
duced by enterococci, such as enterocins A and B, produced by
Enterococcus faecium [10], enterocins DD14 [11] and SL-5 [12], both
identical to MR10A and MR10B [13], enterocin EntV [14] and even
enterocin EF478 [15], which displays sequence similarity to a ser-
ine protease of Enterococcus faecalis. In no case has a thorough
characterization of its therapeutic profile been conducted. Some
studies of immunogenicity and in vivo toxicity have been reported
for some lanthipeptides [16], peptide P34 from Bacillus [17], bacte-
riocins LR14 from Lactobacillus plantarum [18], and TSU4 from Lac-
tobacillus animalis [19].
One of the most interesting classes of bacteriocins, based on
physicochemical characteristics, is the head-to-tail circular pep-
tides produced by Gram-positive bacteria [20]. These biologically
active peptides are post-translationally modified by linkage of
their N- and C-termini via peptide bond, yielding circular active
molecules. They represent a group of antimicrobial peptides that
exhibit broad antimicrobial activity and greater stability and resis-
tance to exoproteases than their unmodified linear counterparts
[20]. For these reasons and because they closely mimic natural
pathways, they have remarkable therapeutic potential in local
and systemic infections [21]. Another advantage is that their
mechanism of action, which specifically targets the bacterial cell
membrane, is novel compared to antibiotics in clinical use, and
bacteria seem less capable of developing resistance towards these
molecules [4,5]. The prototype circular bacteriocin is AS-48, a
70-residue a-helical peptide produced by different strains ofEnterococcus, whose structure, biological activity, and genetic
regulation, have been extensively examined [22]. This peptide
exhibits a strong cidal/lytic activity against most pathogenic
Gram-positive bacteria, including Listeria monocytogenes [23],
Staphylococcus aureus [24], Streptococcus agalactie (unpublished
data), Mycobacterium tuberculosis [25], and Propionibacterium
acnes [26].
The objective of the present study was to characterise the toxi-
cology of the circular bacteriocin AS-48, to determine if it is safe
for clinical/veterinary use. The potency it exhibited against S. aureus
and P. acnes clearly indicates the potential for the use of AS-48 in
treating skin and soft tissue infections caused by these microorgan-
isms. Thus, several biosafety parameters and its functionality have
been analysed using different experimental in vitro models (blood,
human, andmouse cell lines) and in vivo usingmurine and zebrafish
embryomodels. The novelty of this study lies mainly in the scarcity
and limited scope of toxicological analyses of bacteriocins to date,
with the exception of analyses of haemolysis and cytotoxicity
towards tumour cell lines. Thus, to our knowledge, this is a pioneer-
ing article in the field of bacteriocin toxicity in in vivo models.
Material and methods
Bacteriocin AS-48 preparation
AS-48 was purified from supernatants of Enterococcus faecalis
strain UGRA10 [26] cultured in Esprion 300 plus 1% glucose
(E-300-G, DMV Int., Veghel, the Netherlands), using previously
established conditions [27]. The bacteriocin was purified to homo-
geneity (up to 95% purity) by cation exchange and reversed-phase
high-performance liquid chromatography (RP-HPLC) as described
elsewhere [27]. The concentration of purified samples was mea-
sured spectrophotometrically at 280 nm using a Nanodrop 2000
(Thermo Fisher Scientific. Waltham, MA, USA), with the molecular
extinction coefficient 12 490 M1 cm1 according to Gill and von
Hippel [28], the measured molecular weight 7149.5 Da and the
E&MW option.
Haemolytic assays
The haemolytic potential of AS-48 was spectrophotometrically
measured by quantifying haemoglobin released, using whole blood
and defibrinated erythrocytes from 20 human samples (10 males
and 10 females) obtained from the Biobank of Granada (Spain)
(http://www.juntadeandalucia.es/salud/biobanco/) (Public Sani-
tary System of Andalusia) after obtaining the appropriate permits
from the Ethical Research Committees of the Biobank and the
University of Granada (Application number 32130034PV01). Bio-
logical samples were used in compliance with current legislation.
Blood samples from healthy human volunteers were provided in
BD Vacutainer tubes (Becton, Dickinson and Company, Franklin
Lakes, Nueva Jersey, USA) with K2-EDTA as anticoagulant.
For the haemolytic test in whole blood, AS-48 was directly
added to yield different final concentrations (0.5, 1, 2.5, 5, 10, 15,
and 20 mM) in 1 mL of fresh blood. Tubes were slowly stirred at
37 C for 15 min, and cells were removed by centrifugation at
3000 rpm at 4 C for 15 min. Supernatants were diluted 10 fold,
and absorbance (OD) at 540 nm was measured, using fresh blood
diluted 10 fold in MilliQ water as a positive lysis control.
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et al. [29] was performed with some modifications. Briefly, 20 sam-
ples of human red blood cells were isolated from 5 mL of fresh
whole blood by centrifugation at 3000 rpm. Pellets were rinsed
twice in saline solution (0.9% NaCl). The final pellet was resus-
pended in 5 mL of saline solution. Erythrocytes were diluted 10
fold and 800 mL of this suspension was mixed with 200 mL of differ-
ent dilutions of AS-48 samples to achieve final concentration of 0.5,
1, 2.5, 5, 10, 15, and 20 mM. Mixtures were maintained at 37 C for
15 min with slow stirring. Haemoglobin release was quantitated
by measuring optical density at 540 nm (OD540) after centrifuga-
tion (6 min at 3000 rpm, 4 C). Controls with 0 or 100% haemolysis
were obtained by adding 200 mL of saline solution or MilliQ water,
respectively. The percentage of haemolysis (% H) was calculated as
follows: % H = 100  (A  A0)/Atot, with A being the absorbance of
the sample with added AS-48; A0, the absorbance of the negative
control (0.9% NaCl); and Atot, the absorbance of the positive control
(MilliQ water).
Antibacterial activity in blood
Fresh blood samples (0.8 mL) were pre-inoculated with
106 CFU/mL of susceptible Gram-positive bacteria species with
well-known MICs (Listeria monocytogenes CECT4032, Enterococcus
faecalis V583, Staphylococcus aureus CECT240 or Streptococcus
agalactiae Hana-1), and the Gram-negative species Klebsiella pneu-
moniae UGRA-1 (data not shown). These bacterial strains were
grown in brain heart infusion (BHI) or Luria broth (LB) prior to
blood inoculation. The inoculated blood samples were added to dif-
ferent concentrations of AS-48 (0.014, 0.07, 0.14, 0.7 or 1.4 mM in
accordance with their known susceptibilities). Cultures were incu-
bated for 24 h at 37 C with gentle shaking, and samples were
taken at different times (0, 2, 4, 6, and 24 h). Residual CFU/mL of
each indicator bacteria at each time point was determined to quan-
tify death kinetics by plating them on appropriate solid media. All
experiments were performed in triplicate.
Zebrafish embryos acute toxicity assay
The present test for short-term toxicity follows the guidelines of
the OECD Draft Guideline Fish Embryo Toxicity (FET) Test for the
study of chemical substances (May 30, 2006) [30]. The species cho-
sen for this test was the zebrafish (Danio rerio) wild strain AB.
Breeding fish were maintained according to specifications defined
in the technical instruction IT-DD-17, and production of fish eggs
for assays was performed according to the protocol PT-DD12 (Neu-
ron Biopharma, Granada, Spain).
For this assay, normal fertilised eggs were deposited in a 24-
well microplate (10 embryos per concentration). Five final concen-
trations of AS-48 (0.6, 1.4, 3.0, 6.4, and 14.0 mM) were evaluated,
using 3,4-dichloroaniline (3,4-DCA) as a positive control and water
as a negative control. Plates were incubated at 26 ± 1 C for 24 and
48 h post fertilization (hpf), then the embryos were checked for
lethal, sublethal, or teratogenic effects in accordance with proce-
dure outlined by Lammer et al. [31].
In vitro Cytotoxic effects against human cell lines
The effect of AS-48 on the viability in vitro of eukaryotic cells
was assessed in the Cytotoxicity Service of the Medina Foundation
(Granada, Spain) using the colorimetric MTT (3-(4,5-dimethylthia
zole-2-yl)-2,5-diphenyl tetrazolium bromide) assay [32]. Reduc-
tion of tetrazolium to insoluble formazan by cellular enzymes gen-
erates a purple colour. Different concentrations of AS-48 (from 0.27
to 27 mM) were tested against the non-tumour epithelial cells
MCF10A (ATCC CRL-10317) and colonic fibroblast cells CCD18Co(ATCC CRL-1459). Cells were inoculated into 96-well plates
(1  104 cells/well in 200 lL of appropriate culture media) and
incubated overnight at 37 C in 5% CO2. Then, the medium was
replaced, and cells were treated with different concentrations of
AS-48 for 24 h. As positive and negative controls, 8 mM methyl
methane-sulfonate (MMS) and 0.5% DMSO were used, respectively,
with doxorubicin as an internal control. Upon treatment with con-
trols or AS-48, plates were incubated at 37 C in 5% CO2 for 72 h.
The media was then removed from the wells, and MTT was added,
followed by a 3 h incubation period. Dimethyl sulfoxide (DMSO)
was added to solubilise the formazan crystals, and the absorbance
of the obtained solutions was measured at 570 nm using a mul-
tiReader Victor TM (Perkin Elmer Waltham, MA. USA). Viability
data are depicted as the mean percentage ± standard deviations
compared to the control (100%). The results are averages of three
experiments.
Cell viability and nitrite production in treated macrophage RAW cells
The RAW264.7 mouse macrophage tumour cell line was pur-
chased from the Cell Culture Unit of the University of Granada
(Granada, Spain), and cultured in Dulbecco’s Modified Eagle’s Med-
ium (DMEM), supplemented with 10% foetal bovine serum and
2 mM L-glutamine, in a humidified 5% CO2 atmosphere at 37 C.
The effect of AS-48 on cell viability was measured using the Cell
Titer 96 s AQueous One Solution Cell Proliferation Assay (MTS)
from Promega (Madison, WI, USA). Briefly, cells were seeded in
96-well plates and incubated for 2 h with AS-48 (0.27–27 mM),
they were then challenged with 100 ng/mL lipopolysaccharide
(LPS) from Escherichia coli 055:B5 for 24 h to induce expression
and release of cytokines/chemokines. Then, the MTS solution [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul
fophenyl)-2H-tetrazolium] was added to the wells, and absorbance
was measured at 490 nm after 1–4 h at 37 C in a Dynex spec-
trophotometer (Dynex Technologies, Chantilly, VA, USA). Cell via-
bilities were obtained by comparing measured absorbances with
the absorbance of the control cells.
The effect of AS-48 on nitrite production was also evaluated
using cells cultured as described above. After 2-h incubation with
AS-48 followed by 24-h incubation with LPS, cell supernatants
were collected, and nitrite levels were quantified by the addition
of Griess reagent (a coloured azo dye product). Its absorbance
was measured at 540 nm in a Dynex spectrophotometer (Dynex
Technologies, Chantilly, VA, USA) [33].
Local lymph node assay: BrdU-ELISA
Experimental procedures and protocols used in this study were
performed according to the ‘‘Guide to the care and use of labora-
tory animals in research and teaching” [34]. The Commission of
Ethics in Animal Experimentation of the University of Granada
(Spain) approved the experimental protocol (Register number
14-CEEA-OH-2013).
Twenty five CD1 female mice (18–22 g) purchased from the
Laboratory Animal Services of the University of Granada and
maintained in Makrolon cages were provided with food and water
ad libitum in an air-conditioned atmosphere with a 12-h light-dark
cycle. The mice were randomly allocated into five groups (five ani-
mals per group): three groups treated with three different doses of
AS-48 (20, 10, or 1 lg/mouse), a non-treated control group, and a
group treated with phorbol-12-myristate-13-acetate (PMA) as
positive control. Five microliters of AS-48 in the appropriate DMSO
solution was applied to the dorsum of both ears daily for 3 consec-
utive days, whereas control groups received only vehicle. On day 5,
all mice received a single intraperitoneal injection (0.5 mL) of
5-bromo-2-deoxyuridine (BrdU) solution (8 mg/mL). On day 6, a
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measure incorporation of BrdU into lymph node cells using a
CytoSelectTM BrdU Cell Proliferation ELISA Kit from Cell Biolabs
Inc. (San Diego, CA, USA). Briefly, lymph nodes were minced and
resuspended in 20 mL of PBS solution that had been filtered
through a 100-mm mesh. Aliquots of 100 mL were added to a 96-
well flat bottom plate, which was centrifuged at 300g for 10 min.
Seventy five microlitres was removed from each well, and the plate
was dried at 60 C for 1 h. Then, anti-BrdU antibody was added,
and the protocol provided by the kit manufacturer was followed.
BrdU content in each well was measured by reading the absor-
bance at 450 nm in a Dynex spectrophotometer (Dynex Technolo-
gies, Chantilly, VA, USA).In vivo testing of AS-48 in BALB/c mice
Assays were performed according to rules and principles of the
international guide for biomedical research in experimental ani-
mals, including use of the minimum number of animals necessary
to produce statistically reproducible results, and the Three Rs con-
cept (Replacement, Reduction, and Refinement). Seven female
BALB/c mice (10–12 weeks old and 21 g) were selected for these
experiments; they were maintained under standard conditions and
provided with water and standard chow ad libitum. Four mice were
treated with a total of 5 mg/kg (100 lg/mouse) of AS-48 divided
into six doses and administered every 8 h. Mice were intraperi-
toneally injected 200 mL of 11.65 mM (83.34 lg/mL) AS-48 dis-
solved in water. Three negative control mice were administered
only vehicle. After the final injection, the weight of the mice was
determined every 2 days.
Mouse serum samples were obtained 48 h and 7 days after
AS-48 treatment as described Martín-Escolano et al. [35]. Kidney,
heart, and liver marker profiles in serum samples were measured
using a commercial kit from Cromakit with a BS-200 Chemistry
Analyzer (Shenzhen Mindray Bio-medical Electronics Co., Ltd,
Shenzhen, China) in the Scientific Instrumentation Service at the
University of Granada. Finally, two AS-48-treated mice were
euthanised 48 h after treatment, and their spleens were harvested
and weighed to evaluate inflammation. Seven days after treatment,Fig. 1. Percentage of haemoglobin released on exposure to different AS-48 concentrati
results are shown as means ± SD of twenty independent samples.the same procedure was carried out for the other two AS-48-
treated mice and the negative control mice.
Statistical analysis
Statistical analyses were performed using IBM SPSS version 20
(IBM, Spain). Three independent tests were conducted for each
experiment, and data are expressed as mean ± standard deviation
(SD). SPSS one-way ANOVA and LSD post-hoc test were performed
for statistical data analysis. The t-test for paired samples was used
to assess whether there were differences between the assays used,
with P < 0.05 considered statistically significant at a 95% confi-
dence level. Statistical studies based on contingency tables (preva-
lence) together with the 2 test for relationships between
variables were also conducted.Results
Haemolytic activity
The haemolytic potential of purified AS-48 was determined by
the percentage of lysed red cells using whole blood and defibri-
nated human erythrocytes. According to the data obtained, the
haemolytic potential of purified AS-48 varied with assay and con-
centration used. When tested on whole blood, hemolysis produced
by the highest concentrations used (20 lM) was very low (less
than 1.2%). Practically zero haemolysis occurred at concentrations
of 5 lM or lower (Fig. 1).
With defibrinated erythrocytes, the percent haemolysis was 3%
at AS-48 values close to 5 lM, which increased to 15.7 and 22.6% at
10 and 20 lM, respectively (Fig. 1). It is remarkable that lysis
caused by AS-48 on defibrinated erythrocytes required concentra-
tions much higher than those required for antimicrobial activity.
Bactericidal activity of AS-48 in human blood
To investigate the stability and bactericidal activity of AS-48 in
whole human blood, four species of Gram-positive bacteria
(L. monocytogenes CECT4032, E. faecalis V583, S. agalactiae Hana-1ons using whole blood (dark blue) and defibrinated erythrocytes (light blue). The
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pneumoniae UGRA-1) were selected, and their CFU/mL in blood
was monitored over the course of 24-h exposure to different con-
centrations of AS-48. AS-48 concentrations were chosen based on
previously determined MIC values for each bacterium (data not
shown).
A remarkable dose-dependent reduction in bacterial counts
(Fig. 2), which varied with the indicator bacteria used and the
AS-48 concentration added, was observed. Thus, 0.14 lM of
AS-48 completely eradicated L. monocytogenes after 6 h, whereas
S. aureus CECT240 required 24-h incubation. At lower concentra-
tions (0.014 and 0.07 lM) CFU/mL decreased in the first 6 h of
incubation, but total elimination of these bacteria was not
observed (in both cases, approximately 1  104 CFU/mL remained
after 24 h). To eradicate E. faecalis V583 and S. agalactiae Hana-1,
10-fold higher concentrations of AS-48 (1.4 lM) were required to
achieve the same effects seen with L. monocytogenes and S. aureus
(i.e. eradication after 6 and 24 h, respectively). These results
demonstrate that AS-48 is stable in blood for at least 24 h and that
its bactericidal potential remains intact in the presence of blood. As
expected, no inhibition of growth was observed at any AS-48 con-
centrations assayed with K. pneumoniae UGRA-1, which is resistant
to AS-48 (Fig. 2) [36].Assessment of AS-48 toxicity in zebrafish eggs
Zebrafish embryos, which are very sensitive to toxins, were
used to assess the safety, bioavailability, and efficacy of AS-48.Fig. 2. Bactericidal activity of AS-48 against susceptible (Listeria monocytogenes CECT40
aureus CECT240) and resistant bacteria (Klebsiella pneumoniae UGRA-1) previously inoc
concentrations of AS-48 was monitored during 24 h.Embryos exposed to low doses (0.6–3.0 mM) did not display any
visible anomalies after 24 h (Fig. 3).
At concentrations <3 mM, AS-48 was bio-safe even after 48 h of
treatment. At 3 mM, oedema was produced after 48 h in 33.3% of
embryos (Table 1 and Fig. 3). The lethal dose 50 (LD50) was estab-
lished to lie between 3.0 and 6.4 mM, and the maximum tolerated
dose (MTD), at which no toxic or lethal effect could be detected,
was 1.4 mM (10 mg/mL). It is noteworthy that higher doses (6.4
and 14 mM) induced 100% embryo lethality at 24 hpf, during the
most critical stage of embryonic development, when organogene-
sis takes place [37], with filamentous structures visible on the sur-
face of the embryos’ chorion. This lethality could be due to a
membrane dysfunction, calcium imbalance, or outward blebbing
of the cell membrane [38].In vitro toxicity and pro-inflammatory effects of AS-48
The in vitro cytotoxicity of the antimicrobial peptide AS-48 at
concentrations ranging from 0.27 to 27 mM was investigated on
two primary human cell lines (CCD18Co and MCF10A) using the
MTT assay, which measures the mitochondria-dependent meta-
bolic activity of cells. At concentrations close to the MIC, the pres-
ence of AS-48 did not affect these non-tumour human-skin cell
lines. No signs of viability changes were observed even at the high-
est concentration tested (27 mM) (Fig. 4). Statistical analysis
showed no significant differences between the treated cells and
the negative control, confirming the lack of AS-48 toxicity toward
these cell lines under the tested assay conditions (Fig. 4).32, Enterococcus faecalis V583, Streptococcus agalactiae Hana-1 and Staphylococcus
ulated (106 CFU/mL) in human blood. Growth in blood in the presence of different












Fig. 3. Representative stereomicroscopic images of zebrafish embryos exposed to different AS-48 concentrations for 24 and 48 hpf. Images of the negative control (in water)
and the positive control with dichloroaniline (DCA) are also displayed. The images were acquired at 32. Red arrows indicate the formation of oedema that was observed in
33.3% of the treated embryos. The highest AS-48 concentrations tested (6.4 and 14 mM) induced a lethal effect with filamentous structures on the surface of the embryos
chorion.
Fig. 4. Viability of MCF10A and CCDC18Co human cells lines (% in relation to control) after treatment with different concentrations of AS-48. C: control, untreated cells.
Table 1
Percentage of embryos that displayed some type of effect according to AS-48 concentration and time employed (24 and 48 hpf), using 3,4-dichloroaniline (3,4-DCA) as a positive
control and water as a negative control.
AS-48 Cumulative mortality (%) Sub-lethal effects (%) Teratogenic effects (%)
24 hpf 48 hpf 24 hpf 48 hpf 24 hpf 48 hpf
0.64 mM 0 0 0 0 0 0
1.39 mM 0 0 0 0 0 0
3 mM 0 30 0 33.3 0 28.6
6.43 mM 100 100 100 100 100 100
14 mM 100 100 100 100 100 100
Control  0 0 0 0 0 0
Control + 0 60 100 100 100 100
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increasing concentrations of AS-48 (0.27–27 mM) to assess its cyto-
toxicity and possible pro-inflammatory effects. The results showedthat AS-48 had no cytotoxic effects on this tumour cell line at the
concentrations assayed. No significant reduction in cell viability
was observed in these experimental conditions (Fig. 5A).
Fig. 5. AS-48 effect on the viability of the RAW264.7 cells (A) before and after LPS (100 ng/mL) stimulation (B). Data are expressed as means ± SD. The experiments were three
times performed, with each individual treatment being run in triplicate.
Fig. 6. Skin sensitizing potential of AS-48 evaluated in vivo by applying 1, 10, and
20 mg/doses of AS-48 (5 lL) to the dorsum of both ears of CD-1 mice for 3
consecutive days. The proliferation of local lymph node T cells was measured by
incorporation of bromodeoxyuridine (BrdU) by reading the absorbance at 450 nm in
the AS-48 treated mice. Negative (DMSO) and positive (PMA) treated controls.
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phenomenon has been associated with diverse inflammatory dis-
eases ranging from tissue damage to sepsis [39]. Thus, the poten-
tial pro-inflammatory effect of AS-48 was evaluated by
measuring nitrite accumulation in the cell culture medium (an
indicator of nitric oxide synthesis by inducible nitric oxide syn-
thase, also known as iNOS, after macrophage stimulation). In fact,
nitric oxide production is up-regulated in dermal inflammatory
reactions, and its role as a mediator of the irritant response is well
documented [39]. Incubation of RAW264.7 cells with AS-48 (0.27–
27 mM) did not induce nitrite accumulation. Nitrite levels in the
media were similar in treated and control cells (P > 0.05)
(Fig. 5B). However, when nitric oxide production was induced by
LPS (100 ng/mL), AS-48 had a moderating effect, decreasing its pro-
duction in a dose-dependent manner (Fig. 5B). The highest evalu-
ated dose of AS-48 did not have any inhibitory effect, which
could in principle seem paradoxical. However, this is a common
phenomenon when dealing with natural products such as flavo-
noids. These show immunomodulatory properties, ameliorating
inflammatory markers at low doses while showing no effect at
higher ones [40].
Skin sensitizing potential of AS-48
Exposure to a dermal sensitiser results in T-cell proliferation in
local lymph nodes, which can be measured in vivo by the incorpo-
ration of bromo-deoxyuridine (BrdU) [41]. This assay is widely
used to identify products that may cause allergic contact dermati-
tis. In this work, the skin sensitizing potential of AS-48 was evalu-
ated in vivo by applying different doses of AS-48 (1, 10, and
20 mg/doses) or vehicle (20 mL of DMSO) to the dorsum of both ears
of CD-1 mice for 3 consecutive days, and then measuring lympho-
cyte proliferation in local lymph nodes by the BrdU assay and
ELISA. The effect of BrdU incorporation on lymphocytes did not sig-
nificantly differ in the AS-48 treated mice from that in the non-
treated controls (P > 0.05), while PMA-challenged mice showed a
significantly stronger signal (P < 0.05 vs untreated control) (Fig. 6).
In vivo AS-48 toxicity in mice: Tolerability and biochemical analysis
In vivo assays were performed to evaluate AS-48 toxicity at high
concentrations (5 mg/kg) according to several serum biochemical
measurements (% variation of uric acid, urea, creatine kinase-
muscle/brain, lactate dehydrogenase, aspartate aminotransferase,
alanine aminotransferase, alkaline phosphatase, and bilirubin) as
indicators of metabolic disturbances or abnormalities associated
with treatment. AS-48 administration caused an alteration in bio-
chemical parameters in comparison with the negative control
mice, since tolerability trials are based on aggressive treatmentin terms of dose and treatment regimen (Fig. 7). Most of these
parameters returned to normal levels (<20% variation) within
7 days.
Remarkably, none of the treated mice died or lost more than 5%
of their body mass, and all mice returned to their pre-treatment
mass within 7 days. Spleens were weighed to evaluate splenome-
galy as a possible response to AS-48, since this organ is involved
in humoral and cellular immunity against infections. Weight per-
centages of spleens were determined for AS-48-treated (48 h and
7 days post-treatment) and negative control mice (7 days post-
treatment) (Fig. 8). No significant differences were observed for
the different groups of mice, demonstrating that splenomegaly
did not occur in the treated mice.Discussion
The emergence of bacterial resistance to antibiotics, a priority
research area for the National Institute of Health (NIH) and the
World Health Organization (WHO), necessitates the development
of novel antimicrobial therapies: ‘‘novel drug formulations with
novel antimicrobials with unique mechanisms of action and new tar-
gets”. Although some promising agents are currently advancing,
great difficulty is being faced in research on antibacterial drugs
with regard to identifying new molecules with significant antimi-
crobial activity [42]. The reduced effort by pharmaceutical compa-
nies in the last 25 years to develop new antibiotics is adding to this
growing crisis. However, renewed interest in discovery and devel-
opment of new drugs has been observed in the last decade. Much
Fig. 7. Variation (%) of biochemical clinical parameters in mice, measured 48 h and 7 days after AS-48 treatment in comparison to a negative control. Data are expressed as
means ± SD of four (48 h) and two (7 days) independent samples. CK-MB: creatine kinase-muscle/brain; LDH: lactate dehydrogenase; GOT: aspartate aminotransferase; GPT:
alanine aminotransferase; ALP: alkaline phosphatase.
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being extensively studied due to their easy accessibility, few side
effects, low toxicity, and better biodegradability compared to other
available antimicrobial agents, justifying the entry of some of these
products into clinical trials [43].
Broad-spectrum antimicrobial peptides (AMPs), such as LAB
bacteriocins, constitute a promising and exciting therapeutic
option to treat MDR pathogens. Their specificity against microor-
ganisms translates into excellent safety, tolerability, and efficacy
profiles in humans in most cases [21]. The mechanism of action
of most bacteriocins is mainly dependent on their amphiphilic nat-
ure and capacity to insert into and selectivity disrupt bacterial
cytoplasmic membranes [2]. Several bacteriocins (e.g. salivaricin,
nisin A, mersacidin, lacticin 3147, and leucocin A) have been tested
against multi-drug resistant bacteria and even as immune modula-
tors in treating hospital-acquired infections of the skin and muco-
sal wounds, since bacterial membranes have been revealed to be
an important target, even for treating persistent infections [44].
Although efficacy in (mostly) in vitro and/or in vivo models has
been tested for many bacteriocins, a thorough characterization of
their fate upon administration is scarce. PK/PD studies reportedFig. 8. Percentage of spleen weight for negative control mice (untreated) and AS-
48-treated mice 48 h and 7 days after the treatment. Data are expressed as
means ± SD of three (untreated), four (48 h) and two (7 days) independent samples.end in most cases at the level of toxicity, without a careful assess-
ment of administration, distribution, metabolism and excretion
and their impact on efficacy.
One feature of many AMPs that causes much controversy and
complicates drug development is that their antimicrobial activity
is highly sensitive to environmental conditions. Other unfavour-
able properties include their low metabolic stability and their hae-
molytic activity (which are inherent risks of therapeutic peptides
in general) together with salt sensitivity and high cost of produc-
tion [45]. Collectively these are key factors limiting their clinical
application. Remarkably, these features are not relevant for
AS-48, whose cyclic structure confers surprising molecular flexibil-
ity, stability (even in the skin, where Na+ is stored in large
amounts), and resistance to exoprotease degradation, which is
advantageous in therapeutic peptides. The broad antimicrobial
spectrum of the bacteriocin AS-48 at low concentrations
[22,25,26] promotes its application as a new drug for the treatment
of infections caused by microorganisms, including antibiotic-
resistant ones [4,24,26].
Owing to its promise as an antimicrobial agent, the behaviour of
AS-48 has been studied in in vitro and in vivo models to evaluate if
it exhibits some degree of selective toxicity (haemolytic activity,
stability and antibacterial activity in blood, or toxicity against nor-
mal human cell lines, zebrafish embryos, and a murine model). The
in vitro cytotoxicity assays are indicative of the intrinsic ability of a
compound to cause cell death, defining concentration ranges for
safe and rational administration. Overall, these results prove that
AS-48 is safe against fresh human blood at concentrations >10-
fold higher than those needed to inhibit the least sensitive species
tested in this work (1.4 lM to eradicate E. faecalis and S. agalactiae).
Thus, at 20 lM, red blood cell lysis was less than 1.2%, although
with defibrinated erythrocytes, haemolytic activity increased
(22.6% at the same concentration). Nevertheless, this lytic effect
is lower than that shown by the enterocin S37 (74.2% using
10 lg/mL) [46], the lantibiotic nisin (6% using 3.35 lg/mL)
(1 lM) [47] or P34 and P40 peptides from Bacillus (5.84 and
19.3% using 2.5 lg/mL, respectively) (corresponding to 1.7 and
3.12 lM) [17,48]. Bovicin HC5 represents an exception to this pat-
tern (<4% at 200 lM) [49]. These in vitro experiments demon-
strated that AS-48 exhibits a broad bactericidal activity in blood
with no significant haemolytic effect against human erythrocytes,
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known that the antimicrobial activity of cationic peptides can be
attenuated by proteolytic enzymes and divalent cations (which
can hinder the bioavailability of the bacteriocin by competing for
anionic sites of interaction on membranes [50]. In addition, the
presence of albumin, which has a high binding capacity for
hydrophobic compounds, constitutes another check on bacteriocin
efficacy in the bloodstream. For these reasons, one of the major
challenges in developing AS-48 for use as a drug is to verify its sta-
bility and activity in whole blood. This peptide was investigated in
assays that simulated conditions of high titre bacteraemia with dif-
ferent bacterial species. According to our results, AS-48 was stable
in blood for the duration of the time assayed (24 h) and retained its
antimicrobial activity. This behaviour is entirely different from that
shown by the lantibiotic group of bacteriocins, which have reduced
efficacy due to their propensity to bind blood components [50].
Our results indicate a lack of AS-48 cytotoxicity toward the pri-
mary epithelial human cell line MCF10A and the fibroblast line
CCD18Co (currently widely used as controls for drug toxicity), con-
firming its inability to cause cell death or loss of viability in these
human primary cell lines (>90% cell viability) at the highest AS-48
concentration tested (27 lM). This result indicates that AS-48 is
considered non-cytotoxic according to standard international pro-
tocols (UNE-EN ISO 10993-5:2009). Thus, these data confirm that
AS-48 is not toxic towards the non-tumour cell lines tested, in
agreement with results described elsewhere, in which AS-48 was
applied to normal human lung fibroblast MRC-5 cells [50], murine
macrophage lines MHS and J774 [25], and the R1 cell line (ACC 56)
derived from Chinook salmon liver [51]. Although some other pep-
tides have shown a cell-line-specific cytotoxic effect, under the
experimental conditions used here, AS-48 did not affect the normal
cell lines tested at the concentrations assayed, even at 27 lM, a
concentration much higher than its MICs towards bacteria. The
MIC values of AS-48 were around 0.3 lM for P. acnes, one of the
most susceptible bacteria [26], between 0.16 and 0.73 lM for Sta-
phylococcus species [24] and between 4.47 and 8.90 mM for M.
tuberculosis complex clinical and reference strains (the most resis-
tant Gram-positive bacteria described) [25]. Moreover, potent syn-
ergies with lysozyme against P. acnes, with nisin against
Staphylococcus, or with ethambutol against mycobacteria, have
been measured, suggesting that further reductions in dosage are
feasible. The resistance to AS-48 observed in eukaryotic cells was
not unexpected, since eukaryotic membranes lack negatively
charged lipids and contain cholesterol. Other studies have
described the binding of positively charged bacteriocins by nega-
tively charged glycosaminoglycan sulphate residues present in
the proteoglycans of the eukaryotic glycocalyx, which protects
eukaryotic cells against membrane damage [52]. However, in some
eukaryotic organisms, such as parasites with negatively charged
membranes (i.e. trypanosomatids), AS-48 is very effective (even
more than against some bacteria) [53–55].
Likewise, in our in vitro inflammation disorders model, AS-48
did not significantly alter viability or induce nitrite accumulation
in non-stimulated RAW macrophages, demonstrating an absence
of pro-inflammatory effects. Interestingly, AS-48 decreased nitric
oxide (NOx) production induced by LPS (up to 13.5 mM)
(>96.51 mg/mL), which suggests an immunomodulatory function
of AS-48. The observed AS-48 toxicity in in vivo assays performed
using zebrafish embryos could be due to the widespread high rate
of proliferation that occurs during organogenesis (which starts
1 day post-fertilization) and makes these embryos prone to struc-
tural malformations [37]. It is striking that even though assays
using zebrafish embryos for toxicological purposes have been used
for several years, there is a systematic lack of information on bac-
teriocins in such models (even for nisin). Furthermore, there are
few references in the literature using this model with peptides.RhoB-crotamine, a defensin-like cationic peptide that displays
cell-penetrating, antitumor, antimicrobial, antifungal, and antipar-
asitic properties at low micromolar range, was lethal to zebrafish
embryos at all concentrations assayed (0.25–1.0 lM) [38]. In a
recent safety study of the cyclic lipopeptide bacillomycin DC, the
LC50 value after 96 h of exposure was 22.2 lg/mL [56]. In this case,
the estimated lethal dose 50 (LD50) value was between 3 and 6 mM,
and the maximum tolerated dose (MTD) was 1.39 mM. Many fac-
tors may contribute to this behaviour, especially since other non-
toxic proteins, such as bovine serum albumin, widely used as a car-
rier for in vitro experiments on cultured mammalian cells, strongly
affects zebrafish embryos, even at the lowest concentrations tested
(0.5%), resulting in a strong developmental delay [57]. Further-
more, the greater sensitivity of zebrafish embryos to AS-48 may
be explained by the critical development stage of the embryos
and the generally higher toxicity of cationic compounds during this
proliferative phase compared with neutral compounds [37,38].
This may be especially true of immature cells, which are generally
more sensitive to teratogenic effects than fully differentiated cells
[37]. These results, together with the absence of data on the toxi-
city of cationic antimicrobial peptides in zebrafish eggs suggests
that this model may not be the most appropriate to test this type
of compound.
Since topical delivery may be one of the most plausible routes of
administration of AS-48, to circumvent potential adverse systemic
effects [1,58], its pro-inflammatory effects and ability to induce
in vivo lymphocyte proliferation in mice, upon skin sensitization
was assessed. The absence of lymphocyte proliferation in local
lymph nodes after topical exposure to different concentrations of
AS-48 indicates that this peptide does not induce skin sensitization
or cause allergic contact dermatitis.
Finally, our in vivo test in mice to evaluate the impact of a
cumulative AS-48 dose of 5 mg/kg (100 lg/mouse) intraperi-
toneally administered in 6 doses (one every 8 h), revealed that
AS-48 does not produce toxic effects that cause weight loss or sple-
nomegaly. Similar results have been obtained with rainbow trout
after exposure to 13.98 mM of AS-48 for 96 h. Even in the treated
fish, visible signs of abnormality/toxicity were not observed [51].Conclusions
The positive results presented in this work highlight the poten-
tial of AS-48 as a feasible candidate for further pharmacological
development (after carrying out the required clinical trials), to pre-
vent and treat infections, even with multi-drug resistant microor-
ganisms, particularly in skin and soft tissues [4]. Indeed,
bacteriocins produced by LAB probiotic strains have been mar-
keted for skin care, as topical formulations to prevent and treat
skin diseases, including anti-ageing benefits [44]. Global interest
in bacteriocins as natural inhibitory agents to fight diverse infec-
tions is changing perspectives within the pharmaceutical industry
[1,44]. The susceptibilities of several highly sensitive clinical iso-
lates of S. aureus [24] and P. acnes [26] to AS-48 have been success-
fully evaluated, and the application of AS-48 as a topical
antibacterial agent for these types of skin infections has been
patented [59]. The effect of AS-48 either alone or synergistically
combined with other antimicrobial compounds such as lysozyme,
nisin or ethambutol, could further reinforce its utility in diverse
scenarios. AS-48 is also a potential new leishmanicidal agent, and
its use has been suggested for the treatment of ulcers in non-
disseminated cutaneous leishmaniasis [54]. Additional pharma-
cokinetic and in vivo efficacy studies will prove the real applicabil-
ity of AS-48 to treat infections.
The results presented here represent pioneering work in the
field of bacteriocin toxicity in in vivo models, as, despite extensive
138 R. Cebrián et al. / Journal of Advanced Research 20 (2019) 129–139use of bacteriocins in food and abundant literature suggesting their
potential in medicine, there is limited research addressing this
point.
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